

SCHOTT Pharma | 2025


# Facts & Figures



## Global Footprint

17 state-of-the-art production facilities

15 countries, including all major pharma hubs



100% focus  
on our core expertise

Pharma drug containment and  
delivery solutions



€957 million revenues

€258 million EBITDA

(+12% at constant  
currencies)

Margin: 26.9 %



>1,000

patents and designs  
developed

>120

employees  
active in R&D collaborating  
with an exclusive network  
of partners

On average, more than 25,000 injections per minute  
are provided to patients worldwide through a SCHOTT Pharma product.

>12

billion products  
delivered every year



Glass  
syringes



Polymer  
syringes



Cartridges



Vials



Ampoules



Broad  
ready-to-use  
portfolio



# Market & Customers

The top 30 global pharma companies use SCHOTT Pharma's solutions.

**>1,800**

customers worldwide



Big pharma innovators



Leading CDMOs



Biotechs & start-ups

<h2>Growth opportunities from structural trends</h2>	
<p><b>mRNA therapies</b></p> <p>New drug categories require deep-cold storage (-100°C)</p> <div><p>SCHOTT Pharma currently offers the only prefillable syringes for these applications<sup>1</sup></p></div>	<p><b>GLP-1 drugs</b></p> <p>Increasing demand to treat type-2 diabetes, obesity</p> <div><p>SCHOTT Pharma has long-term contracts with the leading GLP-1 players</p></div>
<p><b>Homecare solutions</b></p> <p>Enabling patients to inject drugs at home, reducing healthcare cost</p> <div><p>SCHOTT Pharma contributes to fully integrated systems from device manufacturers</p></div>	<p><b>Manufacturing transformation</b></p> <p>Smaller patient populations require more flexible filling lines</p> <div><p>SCHOTT Pharma offers pre-sterilized, ready-to-use products for utmost flexibility</p></div>
<p><b>Subcutaneous injections</b></p> <p>Subcutaneous large-volume injections of biologics are more patient-friendly</p> <div><p>SCHOTT Pharma's cartridges and syringes feature precise geometry to ensure accurate dosing and reducing injection forces</p></div>	<p><b>Antibody-drug conjugates (ADCs)</b></p> <p>Innovative ADC therapies need to be lyophilized to ensure drug efficacy</p> <div><p>SCHOTT Pharma offers specialty vials that fully eliminate fogging thanks to a hydrophobic inner coating</p></div>

<sup>1</sup>No competitor disclosed a product with mentioned specifications so far



SCHOTT Pharma

# ESG Responsibility



↓

**60%**  
reduced CO<sub>2</sub>  
emissions since 2019<sup>1</sup>

→

**100 %**  
Already using green  
electricity worldwide

  
**~4.700**  
employees from over  
  
**60**  
nationalities

**>40%**  
female employees  
  
**~24 %**  
of leadership positions  
held by women



## Ownership



## Executive Board



**Andreas Risse**  
CEO  
  
Over 35 years of experience  
  
Heading SCHOTT's pharma  
business since 2010  
  
Previously headed SCHOTT's  
Tubing business unit  
  
Master Degree in Industrial  
Engineering



**Dr. Almuth Steinkühler**  
CFO  
  
Over 15 years of experience  
  
Leading the finance  
organization since 2022  
  
Previous management roles with  
thyssenkrupp and Continental  
  
PhD in Management Accounting

<sup>1</sup> Scope 1 & 2; Defined as corporate CO2 footprint of SCHOTT Pharma divided by number of good pieces sold (as of FY 2022)



# SCHOTT Pharma's Governance

**KGaA** (Kommanditgesellschaft auf Aktien) is a listed partnership limited by shares with three corporate bodies:



**General partner**  
(Komplementär)



**Supervisory board**  
(Aufsichtsrat)



**General shareholders' meeting**  
(Hauptversammlung)

As a **popular legal form** for companies originating from families or foundations, there are many **established KGaA** in Germany.

## Supervisory Board


Shareholder representatives



**Peter Goldschmidt**  
CEO  
Stada AG



**Dr. Wolfram Carius**  
Executive Vice President  
Bayer AG



**Eva Kienle**  
CFO  
KWS Saat SE & Co. KGaA



**Ann-Kristin Erkens**  
CFO  
SIG Group AG

## Employee representatives



**Mario Just**  
SCHOTT Pharma



**Christine Wening**  
SCHOTT Pharma

## Press contact



**Lea Kaiser**



[lea.kaiser@schott.com](mailto:lea.kaiser@schott.com)



+49 (0) 151/68 91 71 95

